BenzingaSeptember 17, 2026 at 4:04 AM NYLast Month
Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian marketAsia accounts for nearly two-thirds of lung cancer cases worldwidebioAffinity Technologies, Inc. (NASDAQ:BIAF,
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
